PegBio is Drug Discovery in China that focus on pegylated drugs business. Founded in 2008. They cover business area such as operator, China, development, pegylate drug modification technology, itbe PEG synthesis technology, standardized or special methoxypolyethylene glycol, its derivative, group, succinimide carbonate, succinyl succinimidyl ester, horse Imidazole, access, drug research, biological scientist.
2008
( 16 years old in 2024 )
Pegylated Drugs
-
Room 601, B7 Floor, Biomedicine Industrial Park
No.218 Xinghu Street, Suzhou Industrial Park
Suzhou, Jiangsu 215123
China
Private
operatorChinadevelopmentpegylate drug modification technologyitbe PEG synthesis technologystandardized or special methoxypolyethylene glycolits derivativegroupsuccinimide carbonatesuccinyl succinimidyl esterhorse Imidazoleaccessdrug researchbiological scientist
* We use standard office opening hours in near PegBio's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
PegBio is Drug Discovery business from China that founded in 2008 (16 years old in 2024), PegBio business is focusing on Pegylated Drugs.
PegBio headquarter office and corporate office address is located in Room 601, B7 Floor, Biomedicine Industrial Park No.218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu 215123 China.
PegBio was founded in China.
In 2024, PegBio is currently focus on pegylated drugs sector.
Above is snippet of Google Trends for "pegylated drugs" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with PegBio, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
